ArticleFrontiers in pediatrics2025
Development and validation of a nomogram for early prediction of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and short-term safety of intravenous omadacycline as second-line therapy for macrolide- unresponsive Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Explainable machine learning for diagnosing severeFrontiers in pediatrics · 2026Article
- Construction of a nomogram combining CT and serum markers for predicting macrolide resistance gene mutation status in pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mycoplasma pneumoniae (MP) is a leading cause of community-acquired pneumonia in children, with a significant increase in incidence following the COVID-19 pandemic. The emergence of macrolide-resistant M. pneumoniae (MRMP) has complicated treatment, leading to the concept of macrolide-unresponsive M. pneumoniae pneumonia (MUMPP), defined as lack of improvement after 72 h of macrolide therapy. Early identification of MUMPP is critical for timely intervention and improved outcomes. This study aimed to develop and validate a nomogram for early prediction of MUMPP in children. Methods: We conducted a retrospective study involving 278 pediatric patients with MP pneumonia, divided into training ( Results: Six independent predictors were identified: tree-in-bud pattern, neutrophil-value, lymphocyte-value, creatine kinase (CK), platelet-to-lymphocyte ratio (PLR), and male gender. The nomogram demonstrated strong discriminatory power, with area under the curve (AUC) values of 0.838 (95% CI: 0.779-0.897) in the training set and 0.835 (95% CI: 0.752-0.918) in the validation set. Calibration and DCA confirmed good clinical utility. Conclusion: We developed and validated a simple-to-use nomogram for predicting MUMPP in early stage. The nomogram demonstrates strong discriminatory power and calibration, and may be a practical tool for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.